Corpus ID: 115185743

Cancer esearch apeutics , Targets , and Chemical Biology elopment of a Novel Tumor-Targeted Vascular upting Agent Activated by Membrane-Type R rix Metalloproteinases

@inproceedings{Atkinson2010CancerEA,
  title={Cancer esearch apeutics , Targets , and Chemical Biology elopment of a Novel Tumor-Targeted Vascular upting Agent Activated by Membrane-Type R rix Metalloproteinases},
  author={E. Atkinson and R. Falconer and D. Edwards and C. Pennington and rine S. Siller and S. Shnyder and M. Bibby and L. Patterson and .. Loadman and J. Gill},
  year={2010}
}
Downlo cular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomith tumor shrinkage. Several VDAs have progressed into early clinical trials, but their therapeutic value to be compromised by systemic toxicity. In this report, we describe the design and characterization of a VDA, ICT2588, that is nontoxic until activated specifically in the tumor by membrane-type 1 matrix oproteinase (MT1-MMP). HT1080 cancer cells expressing MT1-MMP were selectively… Expand
1 Citations

Figures and Tables from this paper

Development of PEGylated peptide probes conjugated with (18)F-labeled BODIPY for PET/optical imaging of MT1-MMP activity.

References

SHOWING 1-10 OF 44 REFERENCES
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies
Tumour endoproteases: the cutting edge of cancer drug delivery?
Disrupting tumour blood vessels
Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion.
  • M. Seiki
  • Chemistry, Medicine
  • Cancer letters
  • 2003
...
1
2
3
4
5
...